Cetirizine (Zyrtec, sunizine) inhibits histamine receptors present in the skin, gastrointestinal tract and blood vessels. It is used to treat patients with the following conditions:
- Itching due to urticaria and allergic symptoms of the respiratory tract.
Off-Label Uses of Cetirizine in Adults include
- Anaphylaxis
- Acute allergic and recurrent angioedema
- Reactions due to intravenous medications
Cetirizine (Zyrtec) dose in Adults
Cetirizine (Zyrtec) dose in Allergic rhinitis (runny nose) and conjunctivitis:
- 10 mg once daily. It may be given 2 - 5 hours before exposure to the allergen, however, daily administration is more effective.
For symptoms of hay fever or other upper respiratory allergies as OTC drug:
- 5 to 10 mg once daily to a maximum dose of 10 mg/day.
Off label use of Cetirizine in the treatment of Anaphylaxis as an adjunct to epinephrine for the relief of cutaneous symptoms:
Note: Cetirizine should not be used as monotherapy. It is also not effective in patients with shock and in relieving lower respiratory tract symptoms.
- 10 mg as a single dose
-
Off-label use of Cetirizine in the treatment of acute allergic and recurrent idiopathic Angioedema:
Note: It is not indicated for angioedema with anaphylaxis as it is not effective in the treatment of hypotension and symptoms of lower airway obstruction.
- 10 mg once or two times a day to a maximum dose of 20 mg twice daily
-
Off label use for premedication as an alternative agent in the treatment of Infusion reaction:
- 10 mg administered 30 - 60 minutes before the infusion of certain chemotherapy agents and biologics.
-
Use of Cetirizine in the treatment of acute and chronic spontaneous Urticaria:
- 10 mg once daily initially, the dose may be increased in increments of 10 mg every 1- 4 weeks to a maximum dose of 20 mg twice daily if the symptoms are not controlled.
Cetirizine (Zyrtec) dose in Children
Use of Cetirizine in the treatment of Chronic urticaria in children:
-
Infants 6 - 12 months of age:
- 2.5 mg once daily
-
Children 12 - 23 months of age:
- 2.5 mg once daily initially to a maximum dose of 2.5 mg twice daily
-
Children 2 - 5 years of age:
- 2.5 mg once daily to a maximum dose of 2.5 mg twice daily or 5 mg once daily
Use of Cetirizine in the treatment of Allergic rhinitis:
-
Infants 6 - 12 months of age:
- 2.5 mg once daily
-
Children 12 - 23 months of age:
- 2.5 mg once daily initially to a maximum dose of 2.5 mg twice daily
Use of Cetirizine in the treatment of hay fever and other Allergic symptoms:
-
Children 2 - 5 years of age:
- 2.5 mg once daily to a maximum dose of 2.5 mg twice daily or 5 mg once daily
-
Children older than 6 years and Adolescents:
- 5 to 10 mg once a day.
Pregnancy Risk Factor B
- Cetirizine can be used to relieve allergic symptoms in pregnant women. However, it is best to use the lowest dose.
Cetirizine use during Breastfeeding:
- Breastmilk is enriched with cetirizine.
- Because of its less sedative effects, a second-generation antihistamine might be preferable to the first.
- However, infants should be monitored for irritability and drowsiness.
- Cetirizine can also reduce prolactin secretion, which may cause an increase in milk production in lactating mothers.
Cetirizine (Zyrtec) dose in Renal Disease:
The manufacturer has not recommended any dose adjustment in patients with renal disease, however, the following guidelines may be followed:
-
GFR of more than 50 mL/minute:
- No adjustment in the dose is required
-
GFR of less than 50 mL/minute:
- 5 mg once a day.
-
Intermittent hemodialysis:
- 5 mg once a day or three times a week
-
Peritoneal dialysis:
- 5 mg once a day.
Cetirizine (Zyrtec) dose in Liver Disease:
- The manufacturer has not recommended any dose adjustment in patients with liver disease.
- Because of its sedating properties, it should be used with caution in advanced liver disease.
Common Side Effects of Cetirizine:
- Central nervous system:
- Drowsiness
- Headache
Less Common Side Effects of Cetirizine include:
- Central nervous system:
- Insomnia
- Fatigue
- Malaise
- Dizziness
- Gastrointestinal:
- Abdominal pain
- Xerostomia
- Diarrhea
- Nausea
- Vomiting
- Respiratory:
- Pharyngitis
- Epistaxis
- Bronchospasm
Contraindications to Cetirizine:
Allergy or sensitivity to cetirizine, hydrazine, or any other component of the formulation
Warnings and Precautions
- CNS depression:
- Patients who are using heavy machinery or those who need mental alertness such as driving should use it with caution.
- Hepatic impairment
- In the case of advanced liver disease, use caution.
- Renal impairment
- Patients with a GFR of less than 50 ml/min should be cautious and adjusted accordingly.
Cetirizine (systemic): Drug Interaction
|
Risk Factor C (Monitor therapy) |
|
|
Acetylcholinesterase Inhibitors |
May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. |
|
Alcohol (Ethyl) |
Alcohol's CNS depressing impact may be amplified by CNS depressants (Ethyl). |
|
Alizapride |
May enhance the CNS depressant effect of CNS Depressants. |
|
Amantadine |
CNS depressants may have an enhanced CNS depressant impact. |
|
Amezinium |
Antihistamines may intensify Amezinium's stimulant effects. |
|
Amphetamines |
may lessen antihistamines' sedative effects. |
|
Anticholinergic Agents |
Other anticholinergic agents' negative or hazardous effects could be amplified. |
|
Betahistine |
Betahistine's therapeutic impact may be reduced by antihistamines. |
|
Botulinum Toxin-Containing Products |
may strengthen an anticholinergic agent's anticholinergic action. |
|
Brexanolone |
Brexanolone's CNS depressing effects may be amplified by other CNS depressants. |
|
Brimonidine (Topical) |
May enhance the CNS depressant effect of CNS Depressants. |
|
Bromopride |
May enhance the CNS depressant effect of CNS Depressants. |
|
Cannabidiol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Cannabis |
May enhance the CNS depressant effect of CNS Depressants. |
|
Chloral Betaine |
May enhance the adverse/toxic effect of Anticholinergic Agents. |
|
Chlorphenesin Carbamate |
May enhance the adverse/toxic effect of CNS Depressants. |
|
CNS Depressants |
May enhance the adverse/toxic effect of other CNS Depressants. |
|
Dimethindene (Topical) |
May enhance the CNS depressant effect of CNS Depressants. |
|
Doxylamine |
May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. |
|
Dronabinol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Erdafitinib |
May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. |
|
Esketamine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Gastrointestinal Agents (Prokinetic) |
Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). |
|
Glucagon |
Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. |
|
HydrOXYzine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Itopride |
Anticholinergic Agents may diminish the therapeutic effect of Itopride. |
|
Kava Kava |
May enhance the adverse/toxic effect of CNS Depressants. |
|
Lofexidine |
May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
|
Lumacaftor |
May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. |
|
Magnesium Sulfate |
May enhance the CNS depressant effect of CNS Depressants. |
|
MetyroSINE |
CNS Depressants may enhance the sedative effect of MetyroSINE. |
|
Mianserin |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Minocycline |
May enhance the CNS depressant effect of CNS Depressants. |
|
Mirabegron |
Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. |
|
Mirtazapine |
CNS Depressants may enhance the CNS depressant effect of Mirtazapine. |
|
Nabilone |
May enhance the CNS depressant effect of CNS Depressants. |
|
Nitroglycerin |
Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. |
|
P-glycoprotein/ABCB1 Inducers |
May decrease the serum concentration of Pglycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution ofp-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). |
|
P-glycoprotein/ABCB1 Inhibitors |
May increase the serum concentration of Pglycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of pglycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). |
|
Pilsicainide |
May increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum concentration of Pilsicainide. |
|
Piribedil |
CNS Depressants may enhance the CNS depressant effect of Piribedil. |
|
Pitolisant |
Antihistamines may diminish the therapeutic effect of Pitolisant. |
|
Pramipexole |
CNS Depressants may enhance the sedative effect of Pramipexole. |
|
Ramosetron |
Anticholinergic Agents may enhance the constipating effect of Ramosetron. |
|
Ranolazine |
May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. |
|
ROPINIRole |
CNS Depressants may enhance the sedative effect of ROPINIRole. |
|
Rotigotine |
CNS Depressants may enhance the sedative effect of Rotigotine. |
|
Rufinamide |
May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. |
|
Selective Serotonin Reuptake Inhibitors |
CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. |
|
Tetrahydrocannabinol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Tetrahydrocannabinol and Cannabidiol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Thiazide and Thiazide-Like Diuretics |
Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. |
|
Topiramate |
Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. |
|
Trimeprazine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Risk Factor D (Consider therapy modification) |
|
|
Benzylpenicilloyl Polylysine |
Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. |
|
Blonanserin |
CNS Depressants may enhance the CNS depressant effect of Blonanserin. |
|
Buprenorphine |
CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants. |
|
Chlormethiazole |
May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. |
|
Droperidol |
May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. |
|
Flunitrazepam |
CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. |
|
Hyaluronidase |
Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. |
|
HYDROcodone |
CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
Methotrimeprazine |
CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. |
|
Opioid Agonists |
CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
OxyCODONE |
CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
Perampanel |
May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. |
|
Pramlintide |
May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. |
|
Secretin |
Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. |
|
Sodium Oxybate |
May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. |
|
Suvorexant |
CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. |
|
Tapentadol |
May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. |
|
Zolpidem |
CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. |
|
Risk Factor X (Avoid combination) |
|
|
Aclidinium |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Azelastine (Nasal |
CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). |
|
Bromperidol |
May enhance the CNS depressant effect of CNS Depressants. |
|
Cimetropium |
Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. |
|
Eluxadoline |
Anticholinergic Agents may enhance the constipating effect of Eluxadoline. |
|
Glycopyrrolate (Oral Inhalation |
Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). |
|
Glycopyrronium (Topical) |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Ipratropium (Oral Inhalation) |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Levosulpiride |
Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. |
|
Orphenadrine |
CNS Depressants may enhance the CNS depressant effect of Orphenadrine. |
|
Oxatomide |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Oxomemazine |
May enhance the CNS depressant effect of CNS Depressants. |
|
Paraldehyde |
CNS Depressants may enhance the CNS depressant effect of Paraldehyde. |
|
Potassium Chloride |
Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. |
|
Potassium Citrate |
Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. |
|
Revefenacin |
Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. |
|
Thalidomide |
CNS Depressants may enhance the CNS depressant effect of Thalidomide. |
|
Tiotropium |
Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. |
|
Umeclidinium |
May enhance the anticholinergic effect of Anticholinergic Agents. |
Monitoring parameters:
Monitor the patient's response to therapy, mental status, and anticholinergic effects
How to take Cetirizine?
It is administered without regard to meals. The Chewable tablet should be chewed before swallowing
Mechanism of action of Cetirizine:
Cetirizine is a competitor to histamine receptors found in the gastrointestinal tract and blood vessels as well as the respiratory tract.
The treatment of allergies by inhibiting histamine can result in relief (by using vasoconstrictive properties, and inhibition of the chemotaxis between basophils and eosinophils).
The Onset of Action is about 0.7 hours, and cutaneous allergic symptoms can be suppressed for about 24 hours.
It is rapidly absorbed and is 93% bound with proteins.
The half-life elimination of Cetirizine in children is 6.2 hours, and in adults is 8 hours.
It takes one hour to reach peak serum concentration.
It is excreted mostly via urine, as an unchanged drug.
Cetirizine brand names:
- All Day Allergy Children's
- All Day Allergy
- Allergy Relief
- Allergy
- Relief/Indoor/Outdoor
- Cetirizine HCl Allergy Child
- Cetirizine HCl Children's Allergy
- Cetirizine HCl Hives Relief
- GoodSense All Day Allergy
- Zyrtec Allergy
- Zyrtec Children's Allergy
- Aceterin
- Aceto
- Acidrine
- Acitrin
- Acura
- Adezio
- Agelmin
- Alatro
- Alercet
- Alercina
- Alergine
- Alerid
- Alerid-10
- Allercet
- Allergy-Care
- Allerkid
- Allersan
- Allertek
- Alyr
- Alzyr
- Alzytec
- Amertil
- Anti-Hist Allergy
- Aricetin
- Arix
- Artiz
- Ascet
- Askey
- Askey DT
- Atopix
- Atrizin
- Bluetec
- Cabal
- Ceritec
- Cetallerg
- Cetigen
- Cetihexal
- Cetihis
- Cetimed
- Cetiram
- Cetirax
- CetirHexal
- Cetirin
- Cetiristad
- Cetix
- Cetixin
- Cetizin
- Cetrak
- Cetrimed
- Cetrine
- Cetrix
- Cetro
- Cetymin
- Cezera
- Cezin
- Epirizine
- Estin
- Falergi
- Finallerg
- Gencet
- Glotrizine
- Green Nose
- H-One
- Histacet
- Histacetin
- Histalong
- Histazine
- Histec
- Lergium
- Letizen
- N-Alergya
- Nohist
- Noler
- Nosemin
- Omcet
- Ozen
- Parlazin
- Prixlae
- Razene
- Reactin
- Reactine
- Rolinoz
- Ronex
- Ryvel
- Ryzen
- Ryzicor
- Selitex
- Simtec
- Sunizine
- Sutac
- Talzic
- Terizin
- Texzine
- Tirizine
- Triz
- Trizin 5
- Virlix
- Xero-Sed
- Zensil
- Zericin
- Zertin
- Zertine
- Zetaler
- Zetalerg
- Zetop
- Zilarex
- Zirec
- Zirpine
- Zirtec
- Zirtek
- Zirtin
- Zodac
- Zyllergy
- Zyncet
- Zyrac
- Zyrak
- Zyrcon
- Zyrfar
- Zyrlex
- Zyrrtec
- Zyrtec
- Zyrtec Allergy
- Zyrtec-R
Cetirizine Brands in Pakistan:
|
Cetirizine [Syrup 1 Mg/Ml] |
|
|
Neset |
Surge Laboratories (Pvt) Ltd |
|
Cetirizine [Syrup 1 Mg/5ml] |
|
|
Baydal |
Bayer Health Care |
|
Cetirizine [Syrup 2 Mg/5ml] |
|
|
CLOMIN |
GLITZ PHARMA |
|
Cetirizine [Syrup 5 Mg/5ml] |
|
|
AKSOZINE |
AKSON PHARMACEUTICALS (PVT) LTD. |
|
ALCE |
DERMA TECHNO PAKISTAN |
|
ALERID |
PHARMATEC PAKISTAN (PVT) LTD. |
|
ALGEZEN |
OLIVE LABORATORIES |
|
ALLAMINE |
SHAFAZ PHARMA INTERNATIONAL (PVT) LTD. |
|
ALLOS |
ADAMJEE PHARMACEUTICALS (PVT) LTD. |
|
ALZINE |
BIOGENICS PAKISTAN (PVT) LTD. |
|
ARIX |
TABROS PHARMA |
|
ASKOGIX |
IDEAL PHARMACEUTICAL INDUSTRIES |
|
AVEC |
PLATINUM PHARMACEUTICALS (PVT.) LTD. |
|
CENEX |
DR. RAZA PHARMA (PRIVATE) LIMITED |
|
CERIGEX |
FEDRO PHARMACEUTICAL |
|
CERIZINE |
PHARMEVO (PVT) LTD. |
|
CETRIN |
PARAMOUNT PHARMACEUTICALS |
|
CETRIZA |
SAYYED PHARMACEUTICALS |
|
CETSUN |
HISUN PHARMACEUTICALS |
|
CETZI |
JAWA PHARMACEUTICALS(PVT) LTD. |
|
CEZINE |
P.D.H. PHARMACEUTICALS (PVT) LTD. |
|
CEZIX |
PEARL PHARMACEUTICALS |
|
CISTAZINE |
PHARMEDIC (PVT) LTD. |
|
CITPHARM |
EPHARM LABORATORIES |
|
CITRICARE |
CARE PHARMACEUTICALS |
|
CTZINE |
MEDICRAFT PHARMACEUTICALS (PVT) LTD. |
|
DAVIZIN |
DAVIS PHARMACEUTICAL LABORATORIES |
|
DAYLONG |
TRIGON PHARMACEUTICALS PAKISTAN (PVT) LTD. |
|
DEEBAR |
MEDICEENA PHARMA (PVT) LTD. |
|
DICET |
SHROOQ PHARMACEUTICALS |
|
DOPNIL |
STANDPHARM PAKISTAN (PVT) LTD. |
|
EIDEM |
DELUX CHEMICAL INDUSTRIES |
|
FASTIC |
SEMOS PHARMACEUTICALS (PVT) LTD. |
|
GIXER |
BARRETT HODGSON PAKISTAN (PVT) LTD. |
|
HISTEX |
XENON PHARMACEUTICALS (PVT) LTD. |
|
INCIDAL-NEO |
BAYER HEALTH CARE |
|
INZEE |
INDUS PHARMA (PVT) LTD. |
|
ITIZ |
ZANCTOK PHARMACEUTICALS |
|
LOTOZIN |
LOTUS PHARMACEUTICALS (PVT) LTD |
|
MACRIZINE |
MAC & RANS PHARMACEUTICALS (PVT) LTD |
|
MAXZINE |
MAX PHARMACEUTICALS |
|
MIRAZIN |
MIRACLE PHARMACEUTICALS(PVT) LTD |
|
NEOZINE |
NEO MEDIX |
|
NEUTRIZINE |
NEUTRO PHARMA (PVT) LTD. |
|
NIMZINE |
NIMRALL LABORATORIES |
|
NO ALL |
HARMANN PHARMACEUTICAL LABORATORIES (PVT) LTD. |
|
RAKZINE |
RAKAPOSHI PHARMACEUTICAL (PVT) LTD. |
|
REGOGEX |
REGENT LABORATORIES LTD. |
|
REX |
ALBRO PHARMA |
|
RHIZIN |
CIBEX (PRIVATE) LIMITED |
|
RONEX |
HILTON PHARMA (PVT) LIMITED |
|
ROZEN |
RASCO PHARMA |
|
SAPIZINE |
SAPIENT PHARMA |
|
SEDIL |
SAMI PHARMACEUTICALS (PVT) LTD. |
|
STAMIN |
Shaigan Pharmaceuticals (PVT) LTD |
|
STAND CITRI |
STANDARD DRUG CO. |
|
TICZINE |
LOWITT PHARMACEUTICALS (PVT) LTD |
|
TIRIX |
ALLIANCE PHARMACEUTICALS (PVT) LTD. |
|
ZANLAN |
NOVARTIS PHARMA (PAK) LTD |
|
ZANLAN |
NOVARTIS PHARMA (PAK) LTD |
|
ZECIT |
POLYFINE CHEMPHARMA (PVT) LTD. |
|
ZETRINE |
EFROZE CHEMICAL INDUSTRIES (PVT) LTD. |
|
ZILCIT |
ZINTA PHARMACEUTICALS INDUSTRIES |
|
ZINE |
LIBRA PHARMACEUTICALS (PVT) LTD |
|
ZYRET |
REX PHARMACEUTICALS PAKISTAN |
|
ZYRTEC |
AGP (PRIVATE) LTD. |
|
Cetirizine [Susp 1 Mg/5ml] |
|
|
CETRANEN |
NENZA PHARMACEUTICALS (PVT) LIMITED |
|
Cetirizine [Susp 5 Mg/5ml] |
|
|
CETRAZIT |
ATLANTIC PHARMACEUTICALS (PVT) LTD. |
|
Cetirizine [Soln 5 Mg/5ml] |
|
|
LINAZINE |
ALINA COMBINE PHARMACEUTICALS (PVT) LTD. |
|
Cetirizine [Oral Soln 5 Mg/5ml] |
|
|
RIGIX |
AGP (PRIVATE) LTD. |
|
Cetirizine [Tabs 10 Mg] |
|
|
ACTILIX-CTZ |
GLAXOSMITHKLINE |
|
AKSOZINE |
AKSON PHARMACEUTICALS (PVT) LTD. |
|
ALARZA |
MAX PHARMACEUTICALS |
|
ALARZA |
MAX PHARMACEUTICALS |
|
ALCE |
DERMA TECHNO PAKISTAN |
|
ALCIT |
HIZAT PHARMACEUTICAL INDUSTRIES (PVT) LTD. |
|
ALEGRA |
TAGMA PHARMA (PVT) LTD. |
|
ALER |
LLOYDS PHARMACEUTICALS |
|
ALERGO |
PHARMIX LABORATORIES (PRIVATE) LIMITED. |
|
ALERID |
PHARMATEC PAKISTAN (PVT) LTD. |
|
ALERWISE |
PHARMAWISE LABS. (PVT) LTD. |
|
ALERYAN |
RORYAN PHARMACEUTICAL INDUSTRIES (PVT) LTD |
|
ALERZINE |
MEDERA PHARMACEUTICALS (PVT) LTD. |
|
ALEX |
INNVOTEK PHARMACEUTICALS |
|
ALGEZEN |
OLIVE LABORATORIES |
|
ALLAMINE |
SHAFAZ PHARMA INTERNATIONAL (PVT) LTD. |
|
ALLERGID |
HYGEIA PHARMACEUTICALS |
|
ALLOS |
ADAMJEE PHARMACEUTICALS (PVT) LTD. |
|
ALZEX |
ALSON PHARMACEUTICALS |
|
ALZINE |
BIOGENICS PAKISTAN (PVT) LTD. |
|
AREX |
DANAS PHARMACEUTICALS (PVT) LTD |
|
ARIX |
TABROS PHARMA |
|
ASAZINE |
ZEPHYR PHARMATEC (PVT) LTD. |
|
ASKOGIX |
IDEAL PHARMACEUTICAL INDUSTRIES |
|
ASTEMINE |
SIZA INTERNATIONAL (PVT) LTD. |
|
AVAZIN |
ASKARI PHARMACEUTICALS. |
|
AVEC |
PLATINUM PHARMACEUTICALS (PVT.) LTD. |
|
BAYDAL |
BAYER HEALTH CARE |
|
BAYDAL |
BAYER HEALTH CARE |
|
BIOCIT |
BIOGEN PHARMA |
|
BYTEC |
BATALA PHARMACEUTICALS. |
|
CAYZINE |
CAYLEX PHARMACEUTICALS (PVT) LTD. |
|
CENE |
VEGA PHARMACEUTICALS LTD. |
|
CENEX |
DR. RAZA PHARMA (PRIVATE) LIMITED |
|
CERIDAL |
AXIS PHARMACEUTICALS |
|
CERIGEX |
FEDRO PHARMACEUTICAL |
|
CERIZINE |
PHARMEVO (PVT) LTD. |
|
CET |
WILSHIRE LABORATORIES (PVT) LTD. |
|
CETAHIST |
PHARMACARE LABORATORIES (PVT) LTD. |
|
CETIRIZINE |
PULSE PHARMACEUTICALS |
|
CETRANEN |
NENZA PHARMACEUTICALS (PVT) LIMITED |
|
CETRIAIM |
AIMS TRADERS |
|
CETRIHIT |
UNIPHARMA (PVT) LTD. |
|
CETRIMAK |
MAKSON PHARMACEUTICALS |
|
CETRIN |
PARAMOUNT PHARMACEUTICALS |
|
CETRIX |
DON VALLEY PHARMACEUTICALS (PVT) LTD. |
|
CETSUN |
HISUN PHARMACEUTICALS |
|
CETZI |
JAWA PHARMACEUTICALS(PVT) LTD. |
|
CEZEN |
ENGLISH PHARMACEUTICALS INDUSTRIES |
|
CEZINE |
P.D.H. PHARMACEUTICALS (PVT) LTD. |
|
CEZIX |
PEARL PHARMACEUTICALS |
|
CIPZIN |
LEAMA CHEMI PHARMA (PVT.) LTD. |
|
CISTAZINE |
PHARMEDIC (PVT) LTD. |
|
CITGEN |
GENOME PHARMACEUTICALS (PVT) LTD |
|
CITPHARM |
EPHARM LABORATORIES |
|
CITRESAL |
UNIVERSAL PHARMACEUTICALS (PVT) LTD |
|
CITRISAF |
SAAAF PHARMACEUTICALS |
|
CITRIWEL |
WELMARK PHARMACEUTICALS |
|
CITRIZA |
SAYYED PHARMACEUTICALS |
|
CITZAR |
RORYAN PHARMACEUTICAL INDUSTRIES (PVT) LTD |
|
CONCIDOL |
CONVELL LABORATORIES |
|
COXYZIN |
GLOBAL PHARMACEUTICALS |
|
CTZINE |
MEDICRAFT PHARMACEUTICALS (PVT) LTD. |
|
CYTEN |
BLOOM PHARMACEUTICALS (PVT) LTD. |
|
D-HISTINE |
FLOW PHARMACEUTICALS (PVT) LTD. |
|
DAISY |
MEGA PHARMACEUTICALS (PVT) LTD |
|
DAVIZIN |
DAVIS PHARMACEUTICAL LABORATORIES |
|
DEEBAR |
MEDICEENA PHARMA (PVT) LTD. |
|
DEMAST |
PAKHEIM INTERNANATIONAL PHARMA |
|
DICET |
SHROOQ PHARMACEUTICALS |
|
DOPNIL |
STANDPHARM PAKISTAN (PVT) LTD. |
|
EIDEM |
DELUX CHEMICAL INDUSTRIES |
|
FASTIC |
SEMOS PHARMACEUTICALS (PVT) LTD. |
|
FIRAX |
USAWA PHARMACEUTICALS |
|
FOZIN |
FOZAN PHARMACEUTICALS INDUSTRIERS (PVT) LTD |
|
GIXER |
BARRETT HODGSON PAKISTAN (PVT) LTD. |
|
GRAYZINE |
GRAY`S PHARMACEUTICALS |
|
HEALAZIN |
HEAL PHARMACEUTICALS PVT LTD |
|
HETRIZINE |
SHAWAN PHARMACEUTICALS |
|
HIRAZINE |
21ST CENTURY PHARMACEUTICALS CO. |
|
HISMATEC |
Z-JANS PHARMACEUTICAL (PVT) LTD. |
|
HISMIN |
TRISON RESEARCH LABORATORIES (PVT) LTD |
|
HISTANT |
F.M. PHARMACEUTICALS INTERNATIONAL |
|
HISTEX |
XENON PHARMACEUTICALS (PVT) LTD. |
|
INCIDAL-NEO |
BAYER HEALTH CARE |
|
INCIDAL-NEO |
BAYER HEALTH CARE |
|
INSTAZIN |
FRIENDS PHARMA (PVT) LTD |
|
INZEE |
INDUS PHARMA (PVT) LTD. |
|
ITRAT |
SAYDON PHARMACEUTICAL INDUSTRIES (PVT) LTD. |
|
LINAZINE |
ALINA COMBINE PHARMACEUTICALS (PVT) LTD. |
|
LOTOZIN |
LOTUS PHARMACEUTICALS (PVT) LTD |
|
LZINE |
LINEAR PHARMA |
|
MEDI-H1 |
MEDICON PHARMACEUTICALS INDUSTRIES (PVT) LTD |
|
MISIDOL |
HEALERS LABORATORIES |
|
MUSTEX |
MASS PHARMA (PRIVATE) LIMITED |
|
NAWAZIN |
NAWAN LABORATORIES (PVT) LTD. |
|
NIMIZINE |
NIMRALL LABORATORIES |
|
NIMZINE |
NIMRALL LABORATORIES |
|
NIZEN |
ZEPHYR PHARMATEC (PVT) LTD. |
|
NO ALL |
HARMANN PHARMACEUTICAL LABORATORIES (PVT) LTD. |
|
NOSTAMIN |
SANTE (PVT) LIMITED |
|
NT HIST |
ZESION PHARMACEUTICAL (PVT) LTD |
|
OPTIZIN |
CANDID PHARMACEUTICALS |
|
ORTIZIN |
OBSONS PHARMACEUTICALS |
|
PANAZIN |
PANACEA PHARMACEUTICALS |
|
RAKZINE |
RAKAPOSHI PHARMACEUTICAL (PVT) LTD. |
|
REGOGEX |
REGENT LABORATORIES LTD. |
|
REX |
ALBRO PHARMA |
|
RHIZIN |
CIBEX (PRIVATE) LIMITED |
|
RIGIX |
AGP (PRIVATE) LTD. |
|
RONEX |
HILTON PHARMA (PVT) LIMITED |
|
ROTRAZIN |
ROGEN PHARMACEUTICALS |
|
ROZEN |
RASCO PHARMA |
|
SAPIZINE |
SAPIENT PHARMA |
|
SEDIL |
SAMI PHARMACEUTICALS (PVT) LTD. |
|
SELZINE |
SELMORE AGENCIES |
|
SERZINE |
QINTAR PHARMACUTICALS |
|
STAMIN |
Shaigan Pharmaceuticals (PVT) LTD |
|
STAND CITRI |
STANDARD DRUG CO. |
|
TICKNIL |
SILVER OAK CORPORATION. |
|
TICZINE |
LOWITT PHARMACEUTICALS (PVT) LTD |
|
TIRIX |
ALLIANCE PHARMACEUTICALS (PVT) LTD. |
|
TRINE |
SHAHEEN AGENCIES |
|
TRIZIM |
REX PHARMACEUTICALS PAKISTAN |
|
TRYZIN |
PULSE PHARMACEUTICALS |
|
TYZITEC |
STAR LABORATORIES (PVT) LTD. |
|
URTICAR |
MEDERA PHARMACEUTICALS (PVT) LTD. |
|
VIRLOS |
FERROZA INTERNATIONAL PHARMACEUTICALS (PVT) LTD. |
|
WEBZINE |
WEBROS PHARMACEUTICALS |
|
WINZIM |
WNS FIELD PHARMACEUTICALS |
|
XERO-SED |
HAMAZ PHARMACEUTICAL (PVT) LTD. |
|
XYDEN |
DYSON RESEARCH LABORATORIES |
|
Z-TEK |
PAKHEIM INTERNANATIONAL PHARMA |
|
ZANLAN |
NOVARTIS PHARMA (PAK) LTD |
|
ZANLAN |
NOVARTIS PHARMA (PAK) LTD |
|
ZEATIN |
GLAXOSMITHKLINE |
|
ZEC |
MEDISURE LABORATORIES PAKISTAN (PVT.) LTD. |
|
ZECIT |
POLYFINE CHEMPHARMA (PVT) LTD. |
|
ZETRINE |
EFROZE CHEMICAL INDUSTRIES (PVT) LTD. |
|
ZILCIT |
ZINTA PHARMACEUTICALS INDUSTRIES |
|
ZINE |
LIBRA PHARMACEUTICALS (PVT) LTD |
|
ZINGO |
GOODMAN INTERNATIONAL, |
|
ZINOLUR |
REMINGTON PHARMACEUTICAL INDUSTRIES (PVT) LTD. |
|
ZIRTEK |
HANSEL PHARMACEUTICALS PVT (LTD) |
|
ZYRTEC |
AGP (PRIVATE) LTD. |
|
ZYSIC |
JINNAH PHARMACEUTICALS |
|
ZYTIZINE |
SHAZALS PHARMACEUTICALS |
|
Cetirizine [Caps 10 Mg] |
|
|
CETORID |
HOOVER PHARMACEUTICALS (PVT) LTD |
|
TARCIT |
SEARLE PAKISTAN (PVT.) LTD. |
